A paper examines how deaths should be handled in ALS clinical-trial results
Original source
Functional Loss and Mortality in Randomized Clinical Trials for Amyotrophic Lateral Sclerosis: To Combine, or Not to Combine-That is the Estimand. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Review
- Studied in
- Human
A paper outlines how different ways of handling deaths can change the interpretation of amyotrophic lateral sclerosis (ALS) trial results. It focuses on outcomes such as daily functioning, muscle strength and quality of life, which can be affected when participants die during a trial. The authors say the choice should be made when designing the trial, based on the research question, trial duration, expected treatment effect and study population.
Why this matters
This matters to people taking part in ALS trials because the analysis method affects what a trial result means. It does not show that any treatment works or change current treatment; it addresses how future and existing trial results should be designed and interpreted.
Limitations and context
This is a methodological review and overview, not a clinical trial testing a treatment. It does not provide new evidence that one analysis strategy is superior in every setting. The paper was published in 2022, and its conclusions concern trial design and interpretation rather than patient benefit.